Related Experiment Video
Updated: May 18, 2026
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
Published on: August 2, 2022
Model T muscle CARs can treat brain tumors
1Brain Tumor Immunotherapy Program, Neurosurgery Division, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA. laura.a.johnson@duke.edu
Abstract:
Despite standard treatment with resection, radiation, and chemotherapy, glioblastoma remains a deadly disease with a dismal prognosis. Redirecting patient T cells to target the glioblastoma-associated antigen, IL13Rα2, offers a promising translational immunotherapy with the potential to make a meaningful impact for patients with this disease.
Insights
Glioblastoma is a deadly brain cancer. Redirecting patient T cells to target the IL13Rα2 antigen offers a promising immunotherapy approach for glioblastoma patients.
Area of Science:
- Neuro-oncology
- Immunotherapy
- Cancer immunology
Background:
- Glioblastoma is an aggressive brain tumor with poor patient prognosis despite standard treatments.
- Current therapeutic options including surgery, radiation, and chemotherapy have limited efficacy.
Purpose of the Study:
- To explore the potential of T cell-based immunotherapy targeting the IL13Rα2 antigen in glioblastoma.
- To evaluate a novel therapeutic strategy for improving outcomes in glioblastoma patients.
Main Methods:
- Redirecting patient T cells to recognize and attack glioblastoma cells.
- Targeting the glioblastoma-associated antigen IL13Rα2.
Main Results:
- Immunotherapy targeting IL13Rα2 shows promise in preclinical models.
- This approach offers a potential new avenue for glioblastoma treatment.
Conclusions:
- Targeting IL13Rα2 with T cell immunotherapy represents a promising translational strategy.
- This approach has the potential to significantly improve the prognosis for glioblastoma patients.
